FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Françoise Farace

Research Profile

Chemicals & Drugs

Disorders

Anatomy

Procedures

Physiology

Cytotoxicity, Immunologic

Living Beings

Mouse

Co-author Network

Publications

TOP 3
Christophe Massard; Jean Charles Soria; Melissa Taylor; Marie Cécile Le Deley; isabelle Borget; Carlos Gomez-Roca; Françoise Farace
Prognostic value of circulating VEGFR2+ bone marrow-derived progenitor cells in patients with advanced cancer.
Melissa Taylor; Elodie Tournay; Gilles Vassal; Philippe Vielh; Corinne Laplace-Builhé; Fawzia Louache; Virginie Marty; Paule Opolon; Valérie Rouffiac; Jean-Charles Soria; Fanny Billiot; Patrick Cohen; Françoise Farace
Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells.
Monica Arnedos; Benjamin Besse; Fabrice André; Françoise Farace; Ludovic Lacroix; Caroline Robert; Jean Charles Soria; Alexander M M Eggermont
The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Françoise Farace (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Christophe Massard; Jean Charles Soria; Melissa Taylor; Marie Cécile Le Deley; isabelle Borget; Carlos Gomez-Roca; Françoise Farace
Prognostic value of circulating VEGFR2+ bone marrow-derived progenitor cells in patients with advanced cancer.
European journal of cancer (Oxford, England : 1990) 2012;48(9):1354-62.
2012: Melissa Taylor; Elodie Tournay; Gilles Vassal; Philippe Vielh; Corinne Laplace-Builhé; Fawzia Louache; Virginie Marty; Paule Opolon; Valérie Rouffiac; Jean-Charles Soria; Fanny Billiot; Patrick Cohen; Françoise Farace
Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells.
Cancer discovery 2012;2(5):434-49.
2012: Monica Arnedos; Benjamin Besse; Fabrice André; Françoise Farace; Ludovic Lacroix; Caroline Robert; Jean Charles Soria; Alexander M M Eggermont
The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy.
Molecular oncology 2012;6(2):204-10.
2012: D Malka; Jean-Yves Pierga; N Vimond; E François; Marie-Pierre Galais; P Guichard; N Jacques; Antoine Adenis; V Boige; Eveline Boucher; B Chauffert; Thierry Conroy; F Cvitkovic; Michel Ducreux; Françoise Farace
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(4):919-27.
2012: Rachel Young; Amélie Barthelemy; Benjamin Besse; Fanny Billiot; Françoise Drusch; Françoise Farace; Marianne Oulhen; Emma Pailler; Jean-Charles Soria; Philippe Vielh
Circulating tumor cells in lung cancer.
Acta cytologica 2012;56(6):655-60.
2012: Valérie Boige; Abderrahmane Bourredjem; Nathalie Bouvet-Forteau; Thierry de Baere; Clarisse Dromain; Michel Ducreux; Nathalie Jacques; David Malka; Jean-Pierre Pignon; Nadege Vimond; Charlotte Baey; Françoise Farace
Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma.
The oncologist 2012;17(8):1063-72.
2011: A Lecharpentier; P Perez-Moreno; D Planchard; J C Soria; P Vielh; Françoise Farace
Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer.
British journal of cancer 2011;105(9):1338-41.
2011: Françoise Farace; K Fizazi; N Jacques; L Lacroix; A Laplanche; Sylvestre Le Moulec; C Massard; D Planchard; J C Soria; F André; F Billiot; Anne Chauchereau; F Drusch; N Vimond; P Vielh
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas.
British journal of cancer 2011;105(6):847-53.
2011: Françoise Farace; Marine Gross-Goupil; E Tournay; M Taylor; N Vimond; N Jacques; F Billiot; A Mauguen; C Hill; Bernard Escudier
Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
British journal of cancer 2011;104(7):1144-50.
2010: Melissa Taylor; Jochen Rössler; Birgit Geoerger; Gilles Vassal; Françoise Farace
New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future.
Expert opinion on investigational drugs 2010;19(7):859-74.
2008: Nathalie Jacques; Nadege Vimond; R Conforti; Franck Griscelli; Yann Lecluse; Agnes Laplanche; David Malka; Philippe Vielh; Françoise Farace
Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay.
Journal of immunological methods 2008;337(2):132-43.
2008: Jochen Rössler; Melissa Taylor; Birgit Geoerger; Françoise Farace; Jeanette Lagodny; Regine Peschka-Süss; Charlotte M Niemeyer; Gilles Vassal
Angiogenesis as a target in neuroblastoma.
European journal of cancer (Oxford, England : 1990) 2008;44(12):1645-56.
2007: Celine Haond; Françoise Farace; Martine Guillier; Yann Lécluse; Frederic Mazurier; William Vainchenker; Ali G Turhan
Quantitative and qualitative in vitro analysis of the stem cell potential of hematopoietic cells purified from murine skeletal muscle.
Cell research 2007;17(9):783-91.
2007: Françoise Farace; Christophe Massard; E Borghi; Jean-Michel Bidart; Jean-Charles Soria
Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(8):1421-2.
2007: Françoise Farace; Jean-Michel Bidart
[Circulating endothelial cells: biomarkers for monitoring activity of antiangiogenic therapy].
Bulletin du cancer 2007;94 Spec No():S254-9.
2004: Didier Decaudin; Jean-Marie Vantelon; Jean-Henri Bourhis; Françoise Farace; Marie-Laure Bonnet; Martine Guillier; N Greissenger; M-C Marracho; Assari Shervin; Annelise Bennaceur; Fariba Némati; Jean Michon; Ali G Turhan; C Boccaccio
Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma.
Bone marrow transplantation 2004;34(12):1089-93.
2004: Françoise Farace; prestoz laetitia; Sabrina Badaoui; Martine Guillier; Celine Haond; Paule Opolon; Jean-Leon Thomas; Bernard Zalc; William Vainchenker; Ali G Turhan
Evaluation of hematopoietic potential generated by transplantation of muscle-derived stem cells in mice.
Stem cells and development 2004;13(1):83-92.
2003: Radhia M'kacher; Annelise Bennaceur; Françoise Farace; A Laugé; L F Plassa; E Wittmer; Julien Dossou; Dominique Violot; Eric Deutsch; Jean Bourhis; D Stoppa-Lyonnet; Vincent Ribrag; Patrice Carde; Claude Parmentier; Alain BERNHEIM; Ali G Turhan
Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma.
Oncogene 2003;22(39):7905-12.
2003: Radhia M'kacher; Françoise Farace; Annelise Bennaceur-Griscelli; Dominique Violot; Bernard Clausse; Julien Dossou; Alexander Valent; Claude Parmentier; Vincent Ribrag; Jacques Bosq; Patrice Carde; Ali G Turhan; Alain BERNHEIM
Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model.
Cancer genetics and cytogenetics 2003;143(1):32-8.
2002: Frédérique-Anne Le Gal; Armelle Prevost-Blondel; Renée Lengagne; Marc Bossus; Françoise Farace; Aude Chaboissier; Hélène Gras-Masse; Victor H Engelhard; Jean-Gérard Guillet; Hanne Gahéry-Ségard
Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study.
International journal of cancer. Journal international du cancer 2002;98(2):221-7.
2000: Valérie Molinier-Frenkel; C Le Boulaire; Frédérique-Anne Le Gal; H Gahéry-Segard; Thomas Tursz; Jean-Gérard Guillet; Françoise Farace
Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients.
Human gene therapy 2000;11(13):1911-20.
2000: Valérie Molinier-Frenkel; H Gahery-Segard; Majid Mehtali; C Le Boulaire; S Ribault; Pierre Boulanger; Thomas Tursz; Jean-Gérard Guillet; Françoise Farace
Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes.
Journal of virology 2000;74(16):7678-82.
1999: A Le Cesne; G Vassal; Françoise Farace; Marc Spielmann; T Le Chevalier; Eric Angevin; Dominique Valteau-Couanet; Karim Fizazi; I Cojean; A Llombard; Thomas Tursz; Bernard Escudier
Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(3):268-77.
1998: N Alatrakchi; Françoise Farace; E Frau; Patrice Carde; Jean-Nicolas Munck; Frédéric Triebel
T-cell clonal expansion in patients with B-cell lymphoproliferative disorders.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(5):363-70.
1998: Hanne Gahéry-Ségard; Françoise Farace; D Godfrin; Jessintha Gaston; Renée Lengagne; Thomas Tursz; Pierre Boulanger; Jean-Gérard Guillet
Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity.
Journal of virology 1998;72(3):2388-97.
1997: Hanne Gahéry-Ségard; Valérie Molinier-Frenkel; C Le Boulaire; Patrick Saulnier; Paule Opolon; Renée Lengagne; E Gautier; A Le Cesne; Laurence Zitvogel; Alain Venet; C Schatz; M Courtney; T Le Chevalier; Thomas Tursz; Jean-Gérard Guillet; Françoise Farace
Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products.
The Journal of clinical investigation 1997;100(9):2218-26.
1997: Françoise Farace; Eric Angevin; Isabelle Poullion; C Leboullaire; G Ferir; D Elias; Bernard Escudier; Frédéric Triebel
T-cell receptor CDR3 size distribution analysis to evaluate specific T-cell response to cancer vaccines.
International journal of cancer. Journal international du cancer 1997;71(6):972-7.
1996: A Kumar; Françoise Farace; C Gaudin; Frédéric Triebel
Clonal T cell expansion induced by interleukin 2 therapy in blood and tumors.
The Journal of clinical investigation 1996;97(5):1219-26.
1995: Eric Angevin; Dominique Valteau-Couanet; Françoise Farace; Pierre-Yves Dietrich; A Lecesne; Frédéric Triebel; Bernard Escudier
Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(3):188-95.
1995: Dominique Valteau-Couanet; Hervé Rubie; V Meresse; Françoise Farace; M Brandely; Olivier Hartmann
Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma.
Bone marrow transplantation 1995;16(4):515-20.
1995: Dominique Elias; Françoise Farace; Frédéric Triebel; J M Hattchouel; J P Pignon; A Lecesne; Philippe Rougier; Philippe Lasser; P Duvillard; Bernard Escudier
Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum.
Journal of the American College of Surgeons 1995;181(4):303-10.
1995: Françoise Farace; Eric Angevin; Pierre-Yves Dietrich; C Leboullaire; J Vanderplancke; Bernard Escudier; Frédéric Triebel
Low-dose IL-2 treatment: activation of discrete T- and NK-cell sub-populations in vivo.
International journal of cancer. Journal international du cancer 1995;62(5):523-8.
1995: Bernard Escudier; Françoise Farace; Christine Théodore; Eric Angevin; Bernard Court; D Couanet; Pierre-Yves Dietrich; Stéphane Culine; Marc Pallardy; T Hercend
[Treatment of metastatic kidney neoplasms with a new interleukin 2 protocol: The experience of the Gustave-Roussy Institute].
Bulletin du cancer 1995;82(4):296-302.
1994: Françoise Farace; Eric Angevin; J Vanderplancke; Bernard Escudier; Frédéric Triebel
The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL-2 administration.
International journal of cancer. Journal international du cancer 1994;59(6):752-5.
1994: Françoise Farace; F Orlanducci; Pierre-Yves Dietrich; Catherine Gaudin; Eric Angevin; M H Courtier; Chantal Bayle; T Hercend; Frédéric Triebel
T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(9):4281-90.
1994: C Genevée; Françoise Farace; V Chung; A Diu; C Raffoux; D Charron; T Hercend; Frédéric Triebel
Influence of human leukocyte antigen genes on TCR V gene segment frequencies.
International immunology 1994;6(10):1497-504.
1994: Françoise Farace; F Kremer; Pierre-Yves Dietrich; C Gaudin; Eric Angevin; M H Courtier; Chantal Bayle; T Hercend; Frédéric Triebel
[Repertory of T lymphocytes in patients with stage A chronic lymphoid leukemia: revealed by monoclonal expansion of T cells in vivo].
Bulletin du cancer 1994;81(10):897-9.
1994: E Savelieva; Françoise Farace; Eric Angevin; D Elias; Bernard Escudier; P Duvillard; T Hercend; Frédéric Triebel
T-cell receptor repertoire in colorectal adenocarcinoma patients with hepatic metastases and its changes induced by preoperative adjuvant interleukin-2 therapy.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(1):66-76.
1994: Françoise Farace; Marc Pallardy; Eric Angevin; T Hercend; Bernard Escudier; Frédéric Triebel
Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon gamma: immunological monitoring.
International journal of cancer. Journal international du cancer 1994;57(6):814-21.
1994: Bernard Escudier; Françoise Farace; Eric Angevin; F Charpentier; Gérard Nitenberg; Frédéric Triebel; T Hercend
Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2.
European journal of cancer (Oxford, England : 1990) 1994;30A(8):1078-83.
1993: Françoise Farace; Eric Angevin; Bernard Escudier; Anne Caignard; Pierre-Yves Dietrich; C Genevee; T Hercend; Frédéric Triebel
Influence of interleukin-2 administration on the expression of T-cell receptor V gene segments in patients with renal-cell carcinoma.
International journal of cancer. Journal international du cancer 1993;54(5):741-7.
1993: Pierre-Yves Dietrich; Françoise Farace; Anne Caignard; Bernard Escudier; Frédéric Triebel
[Cancer immunotherapy: immunologic bases, reality and hopes].
Bulletin du cancer 1993;80(7):584-600.
1993: Eric Angevin; Françoise Farace; C Genevée; Michel Henry-Amar; Anne Caignard; Pierre-Yves Dietrich; Bernard Escudier; T Hercend; Frédéric Triebel
Analysis of T-cell-receptor variable gene segment usage in peripheral-blood lymphocytes of advanced cancer patients.
International journal of cancer. Journal international du cancer 1993;54(1):60-7.
1993: Bernard Escudier; Françoise Farace; Eric Angevin; Frédéric Triebel; Sami Antoun; B Leclercq; M Brandely; A Aboudaram; Gérard Nitenberg; T Hercend
Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma.
European journal of cancer (Oxford, England : 1990) 1993;29A(5):724-8.
1992: Françoise Farace; A M Le Ridant; Bernard Escudier; T Hercend; F Triebel
Studies on NK cell purification by negative selection in human peripheral blood.
Biotherapy (Dordrecht, Netherlands) 1992;5(1):11-20.
1990: T Hercend; Françoise Farace; D Baume; F Charpentier; J P Droz; Frédéric Triebel; Bernard Escudier
Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
Journal of biological response modifiers 1990;9(6):546-55.
1990: Françoise Farace; C Mathiot; M Brandely; Thomas Tursz; T Dorval; P Pouillart; Frédéric Triebel; T Hercend; W H Fridman
Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.
Clinical and experimental immunology 1990;82(2):194-9.
1990: P Lang; I Vitté-Mony; Françoise Farace; Rodica Stancou; Frédéric Triebel; Bernard Escudier; T Hercend; Jacques Bertoglio
In vivo activation of LAK cells during systemic IL-2 therapy.
European cytokine network 1990;1(3):185-8.
1988: Françoise Farace; M T Mitjavila; A Betaieb; M C Dokhelar; Joëlle Wiels; Y Finale; NELLY KIEFFER; J Breton-Gorius; William Vainchenker; Thomas Tursz
New hematopoietic differentiation antigens detected by anti-K562 monoclonal antibodies.
Cancer research 1988;48(20):5759-65.
1988: A Bettaieb; Françoise Farace; M T Mitjavila; Z Mishal; M C Dokhelar; Thomas Tursz; J Breton-Gorius; William Vainchenker; NELLY KIEFFER
Use of a monoclonal antibody (GA3) to demonstrate lineage restricted O-glycosylation on leukosialin during terminal erythroid differentiation.
Blood 1988;71(5):1226-33.
1987: A Bettaieb; Jean-Luc Villeval; NELLY KIEFFER; Françoise Farace; L Edelman; J P Cartron; William Vainchenker
Early erythroid markers as probes for normal and leukaemic erythroid differentiation.
Annales de l'Institut Pasteur. Immunology 1987;138(6):877-83.
1986: Françoise Farace; NELLY KIEFFER; B Caillou; W Vainchenker; Thomas Tursz; M C Dokhelar
A 93-kDa glycoprotein expressed on human cultured monocytes and dendritic reticulum cells defined by an anti-K562 monoclonal antibody.
European journal of immunology 1986;16(12):1521-6.